FDA Approves First Drug for Postpartum Depression

The FDA has approved the first drug ever specifically for postpartum depression, Zulresso (brexanolone).

Zulresso is given intravenously. Because of concerns such as sudden loss of consciousness and extreme sedation after administration, the approval of the drug was given with a Risk Evaluation and Mitigation Strategy (REMS). This means that Zulresso will only be available through certified healthcare facilities where a patient can be monitored during the infusion, which takes 60 hours (2.5 days).

Zulresso should be available to women by the end of June.

The most common side effects reported by patients on Zulresso in clinical trials were sleepiness, dry mouth, loss of consciousness and flushing. If a patient’s depression becomes worse or they experience suicidal thoughts and behaviors while on Zulresso, healthcare providers should consider discontinuing the drug.

Zulresso’s efficacy was demonstrated in two double-blind, placebo-controlled trials. In both studies, Zulresso was superior to placebo in terms of reducing depressive symptoms at the end of the infusion and 30 days later.

The drug was granted both Priority Review and Breakthrough Therapy designations by the FDA.

The former is for investigational drugs that may offer a significant improvement in the treatment of a condition; the latter is given to drugs that address an unmet medical need.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Researchers have managed to create artificial red blood cells that can transport medication. Compared to the popular anticoagulant Warfarin, NOAC’s may be superior for treating atrial fibrillation patients with prior intracranial hemorrhage. Also, surgery may be the preferred choice for reducing leg pain in patients with sciatica.  Synthetic Red Blood…

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

  • Advertisement